Essayer OR - Gratuit
AI: One earth, one regulatory ecosystem
Business Standard
|October 24, 2024
Artificial Intelligence (AI) technologies, built on predictive and deterministic analysis of large data sets and patterns, transcend geographies.
AI is inherently collaborative, inclusive, agile, and continuously evolving. Naturally, regulation of AI would need to be, too. Regulatory sandboxes cannot cater to ensuring that the inter-connected, fast-evolving AI benefits all, with minimal risks, globally. Cooperation is essential.
India, with 1.4 billion people, and exponentially increasing digital adoption, will play a key role in this discussion. The benefits of AI extend across domainseconomic, social, health, logistics, education, security, and environment. Evidently, the pace and manner of its adoption into everyday activities is unprecedented. A significant dampener to this adoption is inadequate regulation, encouraging misuse, and impacting user confidence. Risks to security-human, national, economic, social-posed by unregulated advancement and accessibility of AI, are evolving with technology, impacting all stakeholders.
Stakeholders make data - the spine of AI. The larger, more diverse, more inclusive the dataset, the lesser the opportunity for unintended bias, more accurate the assessment and outcome. This makes AI assessment inherently collaborative, inclusive, and cross-jurisdictional, with user confidence critical to its enhancement, and associated risks ubiquitous. The need for collaborative regulation to minimise risks while optimising uptake and enhancement follows naturally.
The current global scenario where AI regulation is fragmented in individualistic sandboxes is sub-optimal.
The race for regulatory "leadership" is counter-intuitive.
There cannot be a legitimate first-mover advantage when effective regulation naturally necessitates cross-jurisdictional collaboration.
Cette histoire est tirée de l'édition October 24, 2024 de Business Standard.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Business Standard
Business Standard
Labour Codes impact: HCL tech profit slips 11%
Q3 top line beats Street estimates, bottom line misses expectations
2 mins
January 13, 2026
Business Standard
New labour Codes, restructuring weigh on TCS earnings
Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.
1 min
January 13, 2026
Business Standard
Black drives the thrill for car buyers
Sees a surge in yearly sales, while white remains practical 'utility king'
2 mins
January 13, 2026
Business Standard
CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS
Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be
2 mins
January 13, 2026
Business Standard
China’s PVC rethink to help India pipe makers
Supply likely to tighten after S-PVC rebate withdrawal
2 mins
January 13, 2026
Business Standard
Responsible growth
India must ensure data centres are sustainable
2 mins
January 13, 2026
Business Standard
India’s GenZ is full of creativity: PM
Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.
1 min
January 13, 2026
Business Standard
Iran wants to negotiate after threats to attack, says Trump
At least 572 killed in protests; Tehran says situation ‘under full control’
2 mins
January 13, 2026
Business Standard
Insurers knock on Irdai door for clarity on director overlap ban
CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY
2 mins
January 13, 2026
Business Standard
Delhi HC allows Zydus to sell generic version of cancer drug
Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.
1 min
January 13, 2026
Listen
Translate
Change font size
